GGrantIndex
Sort

64,565 grants matching drug discovery

Development of SecA as an Antimicrobial Target

$530,161
Cubist Pharmaceuticals, Inc. · R44 · FY2002 · AI

Defining a pathway for mitochondrial heme trafficking

$530,159
Dennis J Stuehr · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · GM

Synthesis and Optimization of the Aleutianamine Class of Alkaloids

$530,142
Mark T Hamann · Medical University Of South Carolina · R01 · FY2024 · GM

Mechanism by which ketogenic diet uncouples tumor growth and overall survival

$530,122
Tobias Janowitz · Cold Spring Harbor Laboratory · R37 · FY2024 · CA

Administrative Core

$530,052
Prakash S. Nagarkatti · University Of South Carolina At Columbia · P20 · FY2018 · GM

1/7 Psychiatric Genomics Consortium: Finding actionable variation

$530,018
Patrick F Sullivan · Univ Of North Carolina Chapel Hill · U01 · FY2020 · MH

Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4

$530,014
Silvia V Montaner · University Of Maryland Baltimore · R01 · FY2016 · EY

Chirality Transfer in Mixed Cation Two-Dimensional Organic-Inorganic Hybrid Perovskites

$530,000
Liang Yan · University Of North Carolina At Chapel Hill · · FY2024 · MPS

Administrative Core

$529,990
Prakash S. Nagarkatti · University Of South Carolina At Columbia · P20 · FY2021 · GM

Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6

$529,984
Laura A Solt · Scripps Florida · R01 · FY2019 · CA

In vivo methods for preclinical analysis of cognitive therapies for schizophrenia

$529,970
Jonathan Max Levenson · Galenea Corporation · RC1 · FY2009 · MH

Discovery and development of potent inhibitors of Jun N-terminal kinase for non-hormonal treatment of endometriosis and associated pain

$529,931
Diana Monsivais · Baylor College Of Medicine · R01 · FY2025 · HD

Low cost custom synthesis microarray

$529,928
Erdogan Gulari · Biodiscovery, Llc · R42 · FY2010 · GM

Preclinical microphysiological tumor models for nuclear medicine

$529,906
Guillem Pratx · Stanford University · R01 · FY2023 · CA

Identification of Pathways that can be Targeted for the Development of Novel Therapies for MRSA

$529,903
Eleftherios Mylonakis · Massachusetts Eye And Ear Infirmary · P01 · FY2015 · AI

ALZHEIMERS RESEARCH PROJECT: Alzheimer's disease drug development

$529,901
Nigel H. Greig · National Institute On Aging · ZIA · FY2025 · AG

Macrofilaricidal Aminoacyl-tRNA Synthetase Inhibitors

$529,866
Michigan State University · U01 · FY2002 · AI

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

$529,860
Prince Joseph Kannankeril · Vanderbilt University · R01 · FY2013 · HL

REST-MED12 Pathways in the Regulation of Estrogen - Progesterone Sensitivity in Uterine Leiomyoma

$529,820
Vargheese Mani Chennathukuzhi · University Of Kansas Medical Center · R01 · FY2025 · HD

Phase I Studies of Targeted Anti-Cancer Therapies

$529,795
Razelle Kurzrock · University Of Tx Md Anderson Can Ctr · U01 · FY2007 · CA

Identification of Rev-Erb alpha/beta nuclear receptor modulators

$529,751
Fraydoon Rastinejad · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2014 · DK

Biology and Engineering of Botulinum Neurotoxins.

$529,745
Min Dong · Boston Children'S Hospital · R01 · FY2025 · NS

Phase I Studies of Targeted Anti-Cancer Therapies

$529,725
Razelle Kurzrock · University Of Tx Md Anderson Can Ctr · U01 · FY2006 · CA

INSECT GLUTAMATE RECEPTORS AS NOVEL INSECTICIDE TARGETS

$529,676
Cambria Biosciences, Llc · U01 · FY2004 · AI

Computer Modeling of G Protein-Coupled Receptors

$529,675
Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK